QSAR, molecular docking, and molecular designs of some anti-epilepsy compounds

Abstract

Epilepsy is a non-communicable central nervous system (CNS) disease that accounts for approximately 0.8–1.2% of the global population at any time. The hyper-activities of gamma butyric acid aminotransferase (GABA_AT) enzyme have been confirmed to be largely responsible for seizure/epilepsy. Because of this special function, the GABA_AT enzyme has been the main target of many anti-epilepsy drugs (AEDs). To date, many discovered AEDs have not eradicated this neurological disease. Since experimental determinations of modern drugs are usually costly and sometimes non-eco-friendly, in-silco quantitative structure–activity relationship (QSAR)-machine learning, docking and pharmacokinetics (PMK) techniques were used to design and test the oral bio-availabilities of all the designed AEDs. QSAR models were generated, and the predictive properties of R²int = 0.9827, R²ext = 0.9407, and R²adj of 0.9667 indicate the evidence that the developed model was not by chance. Six (6) new AEDs were newly designed, and they were found to have better anti-epileptic activities values of 2.146799, 2.224866, 2.31479, 2.450313, 2.301474, and 2.618303 than the standard AED, Vigabatrin (0.40672). Also, the docked new compounds shows excellent binding energies of -127.001, -129.071, -130.515, -126.881, -130.771, and -126.974 kcal/mol compared to the referenced AED (-76.9173 kcal/mol). The PMK and absorption, distribution, metabolism, excretion, and toxicity (ADMET) investigations also revealed that all the designed compounds were found to be bio-available for human administration. ‘Therefore, the newly designed analogues (AEDs) could be considered as potential drug candidates for the treatment of epilepsy.

Keywords

QSAR / AEDs / PMK / ADMET / GABAAT / CNS / Epilepsy

References

[1] KeriRS, Budagumpi S, Balappa SomappaS. Synthetic and natural coumarins as potent anticonvulsant agents: a review with structure–activity relationship. J Clin Pharm Therapeut. 2022;47(7):915–931.

[2] WHO Newsroom. Fact Sheet;February 2015. https://www.who.int/news-room/fact-sheets/detail/epilepsy.

[3] CloydJ, HauserW, TowneA, et al. Epidemiological and medical aspects of epilepsy in the elderly. Epilepsy Res. 2006;68:S39–S48.

[4] CraigI, TallisR. General Practice management of adult–onset epilepsy analyzed. Care Elder. 1991;3:69–72.

[5] SongM, ZhaoW, ZhuY, LiuW, DengX, Huang Y. Design, synthesis, and evaluation of anticonvulsant activities of new triazolopyrimidine derivatives. Front Chem. 2022;10:925281.

[6] SongM, ZhaoW, ZhuY, LiuW, DengX, Huang Y. Design, synthesis, and evaluation of anticonvulsant activities of new triazolopyrimidine derivatives. Front Chem. 2022;10:925281.

[7] Sharma Ramesh, Nakamura Michiko, Neupane Chiranjivi, et al. Il-sung jang, jin bong park. Eur J Pharmacol. 2020;879:173117.

[8] LiC, ChenH, TanQ, et al. The therapeutic and neuroprotective effects of an antiepileptic drug valproic acid in glioma patients. Prog Brain Res. 2020;258:369–379.

[9] McMillinGA, Krasowski MD. Therapeutic drug monitoring of newer antiepileptic drugs. In: Clinical Challenges in Therapeutic Drug Monitoring. Elsevier;2016:101–134.

[10] YuanH. Novel Substrates and Inhibitors of γ-aminobutyric Acid Aminotransferase (GABAAT): Design, Synthesis, Biological Activities, and Mechanistic Studies. Doctoral dissertation, Northwestern University;2006.

[11] James WillmoreL, Abelson MB, Ben-MenachemE, PellockJM, Donald Shields W. Vigabatrin:2008 update. Epilepsia. 2009;50(2):163–173.

[12] EltermanRD, Shields WD, MansfieldKA, NakagawaJ, US Infantile Spasms Vigabatrin Study Group. Randomized trial of vigabatrin in patients with infantile spasms. Neurology. 2001;57(8):1416–1421.

[13] KisZ, Kontoravdi C, ShattockR, ShahN. Resources, production scales and time required for producing RNA vaccines for the global pandemic demand. Vaccines. 2020;9(1):3.

[14] Vincent RajkumarS. The high cost of prescription drugs: causes and solutions. Blood Cancer J. 2020;10(6):71.

[15] BramlageP, Hasford J. Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment–a review. Cardiovasc Diabetol. 2009;8(1):1–13.

[16] TaylorD. The Pharmaceutical Industry and the Future of Drug Development. 2015.

[17] MuratovEN, Kuz’min VE, ArtemenkoAG, et al. New QSPR equations for prediction of aqueous solubility for military compounds. Chemosphere. 2010;79(8):887–890.

[18] FayetG, Rotureau P, JoubertL, AdamoC. Development of a QSPR model for predicting thermal stabilities of nitroaromatic compounds taking into account their decomposition mechanisms. J Mol Model. 2011;17(10):2443–2453.

[19] BaatiN, Nanchen A, StoesselF, MeyerT. Quantitative structure-property relationships for thermal stability and explosive properties of chemicals. Chem Eng Trans. 2013;31(Article):841–846.

[20] AbdulfataiU, UzairuA, UbaS. Molecular docking and quantitative structure-activity relationship study of anticonvulsant activity of aminobenzothiazole derivatives. Beni-Suef Univ J Basic Appl Sci. 2018;7(2):204–214.

[21] UmarBA, UzairuA, ShallangwaGA. Quantum modeling and molecular dynamic simulation of some amino acids and related compounds on their corrosion inhibition of steel in acidic media. Port Electrochim Acta. 2020;38(5):313–329.

[22] AbdulfataiU, UzairuA, ShallangwaGA, UbaS. Designing and estimating antioxidant properties of some lubricant additives via QSPR and MD methodologies. Sci Afr. 2020;8:00451.

[23] IbrahimMT, UzairuA, ShallangwaGA, IbrahimA. In-silico studies of some oxadiazoles derivatives as anti-diabetic compounds. J King Saud Univ Sci. 2020;32(1):423–432.

[24] UmarAB, UzairuA, ShallangwaGA, UbaS. Ligand-based drug design and molecular docking simulation studies of some novel anticancer compounds on MALME-3M melanoma cell line. Egypt J Med Hum Genet. 2021;22(1):1–15.

[25] Usman Abdulfatai, Uzairu Adamu, Uba Sani. Quantitative structure-activity relationship and molecular docking studies of a series of quinazolinonyl analogues as inhibitors of gamma amino butyric acid aminotransferase. J Adv Res. 2016;8:33–43.

[26] Usman Abdulfatai, Uzairu Adamu, Uba Sani. Quantitative structure activity relationship study of anticonvulsant activity of α_substituted acetamido-N-benzylacetamide derivatives. Cogent Chem. 2016;2:1166538.

[27] Usman Abdulfatai, Uzairu Adamu, Shallangwa Gideon Adamu. Molecular docking, design and pharmacokinetics study of some anti-epilepsy compounds. Can Cent Sci Edu. 2021;15(5):67–75.

[28] JakharR, DangiM, KhichiA, Chhillar AK. Relevance of molecular docking studies in drug designing. Curr Bioinf. 2020;15(4):270–278.

[29] VijeshAM, IsloorAM, TelkarS, Arulmoli T, FunHK. Molecular docking studies of some new imidazole derivatives for antimicrobial properties. Arab J Chem. 2013;6(2):197–204.

[30] GuedesIA, de Magalhães CS, DardenneLE. Receptor–ligand molecular docking. Biophysical reviews. 2014;6:75–87.

[31] AltS, Helmstädter A. Market entry, power, pharmacokinetics: what makes a successful drug innovation? Drug Discov Today. 2018;23(2):208–212.

[32] LinJH. Bisphosphonates: a review of their pharmacokinetic properties. Bone. 1996;18(2):75–85.

[33] BourgeoisBF. Pharmacokinetic properties of current antiepileptic drugs: what improvements are needed? Neurology. 2000;55(11 Suppl 3):S11–S16.

[34] BeredaG. What the body does to a drug: pharmacokinetics. J Pharm Pharmacol. 2022;10:316–329.

[35] LipinskiCA, Lombardo F, DominyBW, FeeneyPJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2012;64:4–17.

[36] KamińskiK, Zagaja M, ŁuszczkiJJ, et al. Design, synthesis, and anticonvulsant activity of new hybrid compounds derived from 2-(2, 5-dioxopyrrolidin-1-yl) propanamides and 2-(2, 5-dioxopyrrolidin-1-yl) butanamides. J Med Chem. 2015;58(13):5274–5286.

[37] Łączkowski KrzysztofZ, Sałat Kinga, Misiura Konrad, Adrian Podkowa, Malikowska Natalia. Synthesis and anticonvulsant activities of novel 2-(cyclopentylmethylene)hydrazinyl-1, 3-thiazoles in mouse models of seizures. J Enzym Inhib Med Chem. 2016;31(6):1576–1582.

[38] GóraM, CzopekA, RapaczA, et al. Synthesis, anticonvulsant, and antinociceptive activity of new 3-(2-chlorophenyl)-and 3-(3-Chlorophenyl)-2, 5-dioxopyrrolidin-1-ylacetamides. Molecules. 2021;26:1564.

[39] KamińskiK, Rapacz A, FilipekB, ObniskaJ. Design, synthesis and anticonvulsant activity of new hybrid compounds derived from N-phenyl-2-(2, 5-dioxopyrrolidin-1-yl)-propanamides and -butanamides. Bioorg Med Chem. 2016;24(13):2938–2946.

[40] YapCW. PaDEL-descriptor: an open source software to calculate molecular descriptors and fingerprints. J Comput Chem. 2011;32(7):1466–1474.

[41] NetzevaTI, WorthAP, AldenbergT, et al. Current status of methods for defining the applicability domain of (quantitative) structure-activity relationships: the report and recommendations of ecvam workshop 52. Altern Lab Anim. 2005;33(2):155–173.

[42] PlattsJA, ButinaD, AbrahamMH, Hersey A. Estimation of molecular free energy relation descriptors using a group contribution approach. J Chem Inf Comput Sci. 1999;39(5):835–845.

[43] AbdulfataiU, UzairuA, UbaS. Quantitative structure-activity relationship and molecular docking studies of a series of quinazolinonyl analogues as inhibitors of gamma amino butyric acid aminotransferase. J Adv Res. 2017;8(1):33–43.

[44] Usman Abdulfatai, Uzairu Adamu, Uba Sani. Molecular docking and quantitative structure-activity relationship study of anticonvulsant activity of aminobenzothiazole derivatives. Beni-Suef Univ J Basic Appl Sci. 2018;7(2):204–214.

[45] AbdulfataiU, UbaS, UmarBA, Ibrahim MT. Molecular design and docking analysis of the inhibitory activities of some α_substituted acetamido-N-benzylacetamide as anticonvulsant agents. SN Appl Sci. 2019;1:1–8.

[46] DainaA, Michielin O, ZoeteV. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7(1):42717.

RIGHTS & PERMISSIONS

2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.